Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report. The company managed to reduce its OPEX as it continues its measures for improved cost efficiency. However, the report did not include any major surprises as free cash flow was in line expectation. We anticipate an eventful year ahead for Faron with a revised development plan for bexmarilimab in frontline HR-MDS and multiple IIT studies, and we update our base case valuation.
LÄS MER
